Transmasculine T + Finasteride (Hair Preservation)
Testosterone cypionate standard transmasculine protocol with finasteride added for androgenic alopecia management. Finasteride inhibits 5-alpha-reductase, reducing DHT. For transmasculine patients experiencing or at high risk of male-pattern hair loss on testosterone.
Duration
—
Steps
2
Total Weeks
8
Route
SubQ
Protocols
2
Source
clinical practice
Protocol Timeline
| Step | Weeks | Dose | Compound | Note |
|---|---|---|---|---|
| 1 | 8 | 50 mg | Testosterone Cypionate | 50 mg weekly SubQ or IM. Most common clinical starting dose. Check labs at 6-8 weeks. |
| 2 | 0 | 50 mg | Testosterone Cypionate | Maintenance 50-100 mg weekly. Target trough T: 400-700 ng/dL. |
Rationale
Begin finasteride only after hair loss is evident — preventive use is debated. Monitor for sexual side effects including reduced libido. The transmasculine experience with finasteride is less studied than cisgender male data. Some transmasc people prefer to accept hair loss rather than reduce DHT-mediated effects.
Compounds Used
Related Tools
Track this regimen in Doseline
Adopt Transmasculine T + Finasteride (Hair Preservation) as a template, set reminders for every step, and log doses as you go. All free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.